Fig. 4.

GlyCAM1 prevents inflammatory monocyte entry following radiation therapy. ONHs were collected from 12-month D2.Glycam1 ^−/− and wild-type control mice, cells dissociated, and flow cytometry performed for the inflammatory monocyte markers seen in D2 glaucoma (CD11b, CD11c, CD45) (n > 20/group). Non-irradiated D2.Glycam1 ^−/− mice showed normal monocyte-like cell entry during glaucoma; however, following radiation therapy, some cell entry still occurred in D2.Glycam1 ^−/− optic nerve heads that was most pronounced in the CD11b⁺/CD45^hi cell populations (a, left). There was no significant difference in CD11c⁺ cell populations (a, right). Flow plots are shown in b. Viable cells were gated based on fluorescent staining of CD11b and CD45 (left column), from which CD11b⁺/CD45^hi cells were gated (centre column), and subsequently CD11b⁺/CD45^hi/CD11c⁺ cells. Average values ± standard error of the mean is shown within panels, ***P < 0.001. Thus, Glycam1 has a role in determining monocyte-like cell entry following radiation therapy in D2 glaucoma